Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11738022
Methods for inducing pupil dilation
granted -
US 11738050
Compounds binding to fibroblast activation protein alpha
granted -
US 11738053
Methods and compositions for treating chronic granulomatous disease
granted -
US 11738116
Expanded nanofiber structures comprising electrospun nanofibers and a plurality of holes and methods of making and use thereof
granted -
US 11730717
Melanin-inspired antimicrobial
granted -
US 11730767
Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system
granted -
US 11730760
Laser assisted wound healing protocol and system
granted -
US 11730828
Gene therapy for haploinsufficiency
granted -
US 11732007
Therapeutic compounds and methods
granted -
US 11732037
Weight loss regimen
granted -
US 11730801
Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof
granted -
US 11731968
Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
granted -
US 11725217
Methods to enhance myocardial regeneration and/or repair
granted -
US 11725054
Anti-CD83 antibodies and use thereof
granted -
US 11723992
Method for extraction and purification of 68GA
granted -
US 11723635
Devices and methods for umbilical cord processing
granted -
US 11723982
Methods of treating an ocular disease or disorder
granted -
US 11725008
Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
granted -
US 11723929
Methods of improving cell-based therapy
granted -
US 11723990
Library of pH responsive polymers and nanoprobes thereof
granted -
US 11723864
Antimicrobial and anti-inflammatory compositions
granted -
US 11718630
Compositions and methods for treating cancer
granted -
US 11718613
N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
granted -
US 11718589
Compositions and methods of modulating short-chain dehydrogenase
granted -
US 11717480
Extracellular vesicles and methods and uses thereof
granted -
US 11717542
Using tumor-navigating Salmonella to modulate tumor metabolism
granted -
US 11717573
Methods and compositions for the treatment of cancer
granted -
US 11718596
Amyloid targeting agents and methods of using the same
granted -
US 11718612
Inhibitors of receptor interacting protein kinase I for the treatment of disease
granted -
US 11712467
Methods of rational nicotine hapten design and uses thereof
granted -
US 11712483
Activatable membrane-interacting peptides and methods of use
granted -
US 11713305
Zinc sensors for in vivo imaging of beta-cell function by MRI
granted -
US 11712418
Chemoembolization agents
granted -
US 11713318
Short conjugated oligoelectrolytes and uses thereof
granted -
US 11713313
GLS1 inhibitors for treating disease
granted -
US 11712474
Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
granted -
US 11709216
Cardiac late gadolinium enhancement MRI for patients with implanted cardiac devices
granted -
US 11708637
Methods of supporting a graphene sheet disposed on a frame support
granted -
US 11708352
Anti-cancer compounds
granted -
US 11707535
Method and composition for treating neuropathic pain
granted -
US 11707550
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
granted -
US 11708329
Inhibitors of the WNT/beta-catenin pathway
granted -
US 11702453
Materials and methods for inhibiting flavivirus infection
granted -
US 11702630
In vitro methods of differentiating stem cells into neurons and neurons generated using the same
granted -
US 11702656
Reprogramming of non-neuronal cells into neurons and methods and compositions to treat neurodegenerative diseases and disorders
granted -
US 11702442
Cyclic dinucleotide compounds as sting agonists
granted -
US 11701433
Complexes for delivery of antigenic peptides
granted -
US 11701384
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory